Forgot your password?
New user?
Nanoparticle fear over anti-odour socks
Fragment-based Lead Discovery Conference 2008
test conference
Document Actions
Translational Biomarkers: Pathways to Phase II Survival
October 5 – 7, 2008 | The Crown Plaza Center City | Philadelphia, PA
| Type | Conference |
|---|---|
| Language | English |
| Date |
October 5, 2008
to October 7, 2008 |
| Venue |
, |
| Chemistry Specialties |
|
| Chemistry Techniques |
|
| Contact |
ACS Perspectives , US 1- (800) 227-5558 acsprospectives@acs.org |
| Add event to calendar |
vCal (Windows, Linux)
iCal (Mac OS X)
|
The first ACS ProSpectives conference on translational Biomarkers will be chaired by Dr. Lisa Gold, Executive Director of Merck, and Dr. Paul Galatsis, Associate Research Fellow of Pfizer. Together they have gathered a group of highly regarded pharmaceutical industry and academic scientists who will lecture and present case studies over the course of the two-and-a half-day program. The high attrition rates experienced in Phase II has multiple implications for drug discovery and the pharmaceutical industry in general. This conference is geared specifically for medicinal chemists and focuses on the pathways for developing translational biomarkers. These tools facilitate the translation of preclinical candidates into clinical programs with a greater degree of confidence and have the potential to increase the probability of their success. This program is comprised of three sessions that address key areas of interest for the practicing medicinal chemist. They are: Translatable target engagement biomarkers (imaging and non-imaging biomarkers) Mechanism biomarkers, including safety Clinical biomarkers, including disease biomarkers and regulatory acceptance In each session, four speakers will present on their research addressing and providing their prospective on the session topic. Real life examples will illustrate how the theoretical can be used to address practical issues.